Biohaven CEO Vlad Coric told CNBC Tuesday a current approval of the businesss migraine drug will “change the paradigm” of migraine prevention and treatment. The U.S. Food and Drug Administration recently approved the medication, Nurtec ODT, for preventative treatment of migraines. That happens a year after Nurtec was first launched to treat the signs of incapacitating headaches, making it the first pill authorized for both severe treatment and avoidance, according to Coric. “This is a huge approval for Biohaven and clients with migraine,” Coric said in a “Mad Money” interview with Jim Cramer. “Ive been practicing medicine for 25 years, and this is the very first time we have a single migraine medication that can do both of these things,” Coric stated. “This is going to alter the paradigm in which migraine is treated.”The New Haven, Connecticut-based pharmaceutical business has recruited celebrity names like starlet Whoopi Goldberg and design Khloe Kardashian to promote the therapy.Biohaven shares closed at $95.36 each Tuesday, up 6.5% from where it last traded before the announcement.